196 related articles for article (PubMed ID: 23019417)
1. Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.
Buoncervello M; Borghi P; Romagnoli G; Spadaro F; Belardelli F; Toschi E; Gabriele L
Neoplasia; 2012 Sep; 14(9):855-67. PubMed ID: 23019417
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Hodge JW; Garnett CT; Farsaci B; Palena C; Tsang KY; Ferrone S; Gameiro SR
Int J Cancer; 2013 Aug; 133(3):624-36. PubMed ID: 23364915
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
4. Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Hashemi-Niasari F; Rabbani-Chadegani A; Razmi M; Fallah S
Biomed Pharmacother; 2018 Oct; 106():858-867. PubMed ID: 30119256
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
Karaca B; Degirmenci M; Ozveren A; Atmaca H; Bozkurt E; Karabulut B; Sanli UA; Uslu R
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1273-80. PubMed ID: 25925002
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
8. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Magnetto S; Boissier S; Delmas PD; Clezardin P
Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
[TBL] [Abstract][Full Text] [Related]
10. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
11. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
[TBL] [Abstract][Full Text] [Related]
12. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
16. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity.
Yuan Q; Han J; Cong W; Ge Y; Ma D; Dai Z; Li Y; Bi X
Int J Nanomedicine; 2014; 9():4829-46. PubMed ID: 25378924
[TBL] [Abstract][Full Text] [Related]
18. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
